



SDI Review Form 1.6

Journal Name:	<u>Journal of Cancer and Tumor International</u>
Manuscript Number:	Ms_JCTI_31424
Title of the Manuscript:	Case Report of Prolonged Stable Disease with Modified Schedule Sunitinib in Metastatic Renal Cell Carcinoma
Type of the Article	Case Report

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Continuation or discontinuation of the TKI therapy is important issue that have to be carefully reviewed for every patient. This case report can be helpful for other physicians. Some revisions (stated) are needed.	
Minor REVISION comments	Depending on country sunitinib is sometimes recommended as second line treatment option (for mRCC), therefore country f treatment should be stated in the manuscript. What is more, in background section information about sunitinib (and guidelines) should be referenced.	
Optional/General comments	Grammatical errors that should be corrected.	

Reviewer Details:

Name:	<i>Łukasz Szymański</i>
Department, University & Country	<i>Department of Oncology, Military Institute of Medicine, Poland and Institute of Genetics and Biotechnology, Faculty of Biology, Warsaw University, Poland and Department of Microwave Safety, Military Institute of Hygiene and Epidemiology, Poland</i>